MX342798B - Compuesto de ácido (2s)-2-amino-3-(3,4-bis((2-(benzoiloxi)-2-metil propanoil)oxi)-fenil)propanóico y uso médico del mismo. - Google Patents

Compuesto de ácido (2s)-2-amino-3-(3,4-bis((2-(benzoiloxi)-2-metil propanoil)oxi)-fenil)propanóico y uso médico del mismo.

Info

Publication number
MX342798B
MX342798B MX2013006128A MX2013006128A MX342798B MX 342798 B MX342798 B MX 342798B MX 2013006128 A MX2013006128 A MX 2013006128A MX 2013006128 A MX2013006128 A MX 2013006128A MX 342798 B MX342798 B MX 342798B
Authority
MX
Mexico
Prior art keywords
levodopa
overcomes
medical use
novel compound
prodrug
Prior art date
Application number
MX2013006128A
Other languages
English (en)
Other versions
MX2013006128A (es
Inventor
Yano Koji
Kokubo Masaya
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2013006128A publication Critical patent/MX2013006128A/es
Publication of MX342798B publication Critical patent/MX342798B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee un profármaco de levodopa que supera los problemas atribuidos a la cinética sanguínea del levodopa tal como el gran número de dosis y la incidencia de efectos secundarios debidos a la frecuente dosificación. El ácido (2S)-2-amino-3-(3,4-bis((2-(be nzoiloxi)-2-metilpropanoil)oxi)-fenil)propanoóico, una sal del mismo, o un solvato del mismo es un profármaco de levodopa, y provee un perfil constante de concentración en sangre-tiempo de levodopa a través de administración oral, y por lo tanto es útil como un agente preventivo y/o terapéutico para la enfermedad de Parkinson y/o síndrome de Parkinson que supera los problemas asociados con preparaciones farmacéuticas de levodopa.
MX2013006128A 2010-12-02 2011-12-01 Compuesto de ácido (2s)-2-amino-3-(3,4-bis((2-(benzoiloxi)-2-metil propanoil)oxi)-fenil)propanóico y uso médico del mismo. MX342798B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010269046 2010-12-02
PCT/JP2011/077834 WO2012074069A1 (ja) 2010-12-02 2011-12-01 新規化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
MX2013006128A MX2013006128A (es) 2013-07-03
MX342798B true MX342798B (es) 2016-10-13

Family

ID=46171994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006128A MX342798B (es) 2010-12-02 2011-12-01 Compuesto de ácido (2s)-2-amino-3-(3,4-bis((2-(benzoiloxi)-2-metil propanoil)oxi)-fenil)propanóico y uso médico del mismo.

Country Status (21)

Country Link
US (2) US8748485B2 (es)
EP (1) EP2647619B1 (es)
JP (1) JP5423905B2 (es)
KR (1) KR20130121902A (es)
CN (1) CN103228618B (es)
AU (1) AU2011337596B2 (es)
BR (1) BR112013013551A2 (es)
CA (1) CA2818161A1 (es)
DK (1) DK2647619T3 (es)
ES (1) ES2529129T3 (es)
HK (1) HK1184779A1 (es)
IL (1) IL226672A (es)
MX (1) MX342798B (es)
MY (1) MY160914A (es)
NZ (1) NZ612636A (es)
PL (1) PL2647619T3 (es)
PT (1) PT2647619E (es)
RU (1) RU2570900C2 (es)
TW (1) TWI534125B (es)
WO (1) WO2012074069A1 (es)
ZA (1) ZA201304012B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209302B1 (en) 2014-10-21 2019-04-24 AbbVie Inc. Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
RU2678977C1 (ru) * 2018-04-12 2019-02-05 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции тремора в эксперименте
CN109820862A (zh) * 2019-02-21 2019-05-31 山东大学 D-甘露糖在制备抵抗多巴胺减少和/或提升多巴胺水平产品中的应用
CN118141772B (zh) * 2024-03-08 2024-09-10 四川鲁徽制药有限责任公司 盐酸罗匹尼罗甲磺酸雷沙吉兰复方口崩控释片及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (es) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
CH562199A5 (es) * 1970-10-30 1975-05-30 Hoffmann La Roche
BE793426A (fr) 1971-12-28 1973-06-28 Lannacher Heilmittel G M B H Derives de phenylalanine
ZA733990B (en) * 1972-06-17 1974-05-29 Whitefin Holding Sa Beta(3,4-dialkanyloxyphenyl)-l-alanines
ZA734698B (en) 1972-08-02 1974-06-26 Whitefin Holding Sa Esters of beta-(3,4-dialkanoyloxyphenyl)-l-alanines
US3998799A (en) 1973-11-02 1976-12-21 Interx Research Corporation Novel, transient pro-drug forms of l-dopa
FR2277575A1 (fr) * 1974-07-10 1976-02-06 Synthelabo Nouveaux derives de la dihydroxy-3,4 phenylalanine, leurs sels, leur preparation et les medicaments qui en contiennent
US4065566A (en) 1975-04-17 1977-12-27 Interx Research Corporation N-Nicotinoyl-3,4-dinicotinoyloxy-L-phenylalanine and derivatives pharmaceutical compositions and methods containing same
JPH10512248A (ja) * 1995-01-13 1998-11-24 ノバルティス アクチェンゲゼルシャフト 農薬特性を有する４−アリール−及び４−ヘテロアリール−５−オキソ−ピラゾリン誘導体
JP3485375B2 (ja) 1995-02-17 2004-01-13 株式会社資生堂 皮膚外用剤
JP4243716B2 (ja) 2003-06-10 2009-03-25 日清食品ホールディングス株式会社 哺乳動物細胞を用いた変異原性試験法
KR100625999B1 (ko) 2004-02-26 2006-09-20 삼성에스디아이 주식회사 도너 시트, 상기 도너 시트의 제조방법, 상기 도너 시트를이용한 박막 트랜지스터의 제조방법, 및 상기 도너 시트를이용한 평판 표시장치의 제조방법
ZA200610042B (en) 2004-06-04 2008-06-25 Xenoport Inc Levodopa prodrugs, and compositions and uses thereof
US7323585B2 (en) 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
DE102005022276A1 (de) 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivate von Dihydroxyphenylalanin
JP4961135B2 (ja) 2005-11-24 2012-06-27 国立大学法人東京農工大学 立体画像記録体
DK1959948T3 (da) 2005-12-05 2012-08-20 Xenoport Inc Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
GB0605295D0 (en) 2006-03-16 2006-04-26 Proximagen Ltd Amino and derivatives
AU2007231488A1 (en) 2006-03-24 2007-10-04 National Research Council Of Canada Anti-diabetic cataract compounds and their uses
US7709527B2 (en) 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
US7829592B2 (en) * 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
GB0715712D0 (en) 2007-08-11 2007-09-19 Proximagen Ltd Amino acid derivatives
KR20100112573A (ko) 2007-12-14 2010-10-19 이 아이 듀폰 디 네모아 앤드 캄파니 수계 전기코팅을 위한 무 유기용매 안료 분산제
WO2009101616A1 (en) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
US8045264B2 (en) 2009-03-20 2011-10-25 Skyline Displays, Inc. Projection backwall apparatus and system

Also Published As

Publication number Publication date
AU2011337596B2 (en) 2016-07-07
EP2647619A4 (en) 2013-10-09
RU2013129917A (ru) 2015-01-10
US20130245074A1 (en) 2013-09-19
JP5423905B2 (ja) 2014-02-19
WO2012074069A1 (ja) 2012-06-07
ZA201304012B (en) 2014-02-26
ES2529129T3 (es) 2015-02-17
PT2647619E (pt) 2015-02-20
RU2570900C2 (ru) 2015-12-20
MY160914A (en) 2017-03-31
TW201307257A (zh) 2013-02-16
EP2647619A1 (en) 2013-10-09
DK2647619T3 (en) 2015-03-02
HK1184779A1 (en) 2014-01-30
MX2013006128A (es) 2013-07-03
US20140187630A1 (en) 2014-07-03
EP2647619B1 (en) 2015-01-21
US8748485B2 (en) 2014-06-10
CN103228618B (zh) 2016-02-17
CN103228618A (zh) 2013-07-31
AU2011337596A1 (en) 2013-07-18
JPWO2012074069A1 (ja) 2014-05-19
CA2818161A1 (en) 2012-06-07
BR112013013551A2 (pt) 2016-10-11
IL226672A (en) 2016-04-21
TWI534125B (zh) 2016-05-21
KR20130121902A (ko) 2013-11-06
PL2647619T3 (pl) 2015-08-31
NZ612636A (en) 2015-01-30

Similar Documents

Publication Publication Date Title
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
EA201390332A1 (ru) Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
PH12015500313A1 (en) Orally administered medical composition
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ601595A (en) Oral formulations and lipophilic salts of methylnaltrexone
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
NZ714963A (en) Compositions and methods for treating anemia
MX342798B (es) Compuesto de ácido (2s)-2-amino-3-(3,4-bis((2-(benzoiloxi)-2-metil propanoil)oxi)-fenil)propanóico y uso médico del mismo.
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
NZ598489A (en) Combination therapy for treating proliferative diseases
NZ594184A (en) Skin treatment
RS20080497A (en) Novel low dose pharmaceutical compositions comrising nimesulide, preparation and use thereof
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
EP3404029A3 (en) Pyrimido-pyridazinone compounds and methods and use thereof
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
EP2545929A4 (en) ENHANCING OR TREATING AGENT FOR CHRONIC PROSTATITIS, INTERSTITIAL CYSTITIS AND / OR MICTION DISORDERS
MX2019003470A (es) Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
IN2014DN11023A (es)
NZ597675A (en) Medicament for the long term nsaid use

Legal Events

Date Code Title Description
FG Grant or registration